天际股份(002759) - 2025 Q2 - 季度业绩预告

Core Performance Forecast (H1 2025) The company anticipates a net loss for H1 2025, significantly narrowing from the prior year, with net profit attributable to shareholders projected at a loss of 50 million to 65 million CNY, compared to a loss of 127.7243 million CNY in the same period last year Core Performance Forecast (H1 2025) Table | Item | Current Reporting Period (H1 2025) (million CNY) | Prior Period (H1 2024) (million CNY) | | :--- | :--- | :--- | | Net Profit Attributable to Shareholders | Loss of 50 million – 65 million CNY | Loss of 127.7243 million CNY | | Net Profit After Deducting Non-Recurring Gains and Losses | Loss of 50 million – 65 million CNY | Loss of 128.2775 million CNY | | Basic Earnings Per Share | Loss of 0.10 – 0.13 CNY/share | Loss of 0.25 CNY/share | - The company explicitly forecasts a net loss for its operating performance in H1 2025[3] Forecast Audit Status This performance forecast represents preliminary estimates by the company's finance department and has not been pre-audited by a certified public accountant - This performance forecast has not been pre-audited by a certified public accountant[3] Analysis of Performance Changes During the reporting period, the company significantly reduced its losses, primarily due to effective cost reduction and control measures in the lithium hexafluorophosphate business, though this core segment still incurred losses due to industry overcapacity and low selling prices, while phosphochemical products achieved slight profitability and small home appliance business remained largely breakeven - The primary reason for the company's significant loss reduction is the effectiveness of cost reduction and control measures in the lithium hexafluorophosphate business segment[5][6] - The main reason for the company's overall loss is its core product, lithium hexafluorophosphate, where sales prices are below full cost due to temporary industry overcapacity and intense market competition[4] - Other business segments performed stably: subsidiary Xinte Chemical's phosphochemical products achieved slight profitability, while the small home appliance business segment was largely breakeven[4] Risk Warning The company advises investors that this performance forecast is based on preliminary estimates, and the final accurate financial data will be subject to the official 2025 semi-annual report, urging investors to be mindful of investment risks - This performance forecast data is a preliminary estimate and may differ from the final semi-annual report, so investors are advised to exercise caution in their decisions[7]